Corporate Structure and Governance - The company established a wholly-owned subsidiary, Tianjin Weiming Biomedical Co., Ltd., to align with its strategic development needs, completing the transfer of 60.57% equity from Xiamen Weiming[1]. - The company directly holds 26.91% equity in Beijing Kexing Biological Products Co., Ltd. after the internal equity transfer from its wholly-owned subsidiary[2]. - The company ensures independent operations from its controlling shareholder, maintaining complete separation in business, personnel, assets, organization, and finance[23]. - The board of directors and supervisory board operate independently, adhering to relevant laws and regulations, ensuring effective governance[24][25]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, enhancing accountability[34]. - The company has a dedicated investor relations management system, ensuring timely and accurate information disclosure to all shareholders[28]. - The company has no related party transactions or competition with its controlling shareholder, as confirmed by a commitment letter from the shareholder[41]. - The company maintains an independent financial management system, with a dedicated finance team and separate bank accounts[43]. - The company has implemented a comprehensive internal governance structure, with various regulations updated as of November 2022[36][40]. - The company emphasizes the protection of stakeholders' rights, promoting a balanced approach to social, shareholder, and employee interests[35]. - The company has a clear organizational structure that operates independently from its controlling shareholder, ensuring no interference in business operations[43]. - The board of directors has undergone changes, with several members resigning due to term expiration[72]. - The company has received a qualified audit opinion for its 2022 financial statements, indicating areas requiring attention[32]. - The company has detailed major risks in the report, including policy risk, R&D risk, safety and environmental risk, and market competition risk[47]. - The company has implemented new strategies for stability and growth, as discussed in board meetings, highlighting a proactive approach to market challenges[158]. - The company has maintained a high attendance rate at board meetings, with key directors participating in all sessions, ensuring strong oversight[164]. Financial Performance - The company reported a total revenue of 286.53 million in the fiscal year 2022[66]. - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15% compared to RMB 1.04 billion in 2021[96]. - The net profit attributable to shareholders for 2022 was RMB 150 million, a decrease of 10% from RMB 167 million in 2021[96]. - The company's operating revenue for 2022 was ¥357,080,537.01, a decrease of 11.33% compared to ¥402,713,045.66 in 2021[109]. - The net profit attributable to shareholders for 2022 was -¥14,689,829.85, representing a decline of 105.42% from ¥271,001,671.69 in 2021[109]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥8,497,675.71, down 103.33% from ¥255,223,170.55 in the previous year[109]. - The net cash flow from operating activities was -¥54,485,087.46, a decrease of 18.41% compared to -¥46,015,293.51 in 2021[109]. - The basic and diluted earnings per share for 2022 were -¥0.0223, a drop of 105.43% from ¥0.4108 in 2021[109]. - The weighted average return on net assets was -0.62% at the end of 2022, compared to 12.03% at the end of 2021[109]. - The total assets of the company as of December 31, 2022, were RMB 3 billion, reflecting a 5% increase from RMB 2.86 billion in 2021[96]. - The total assets at the end of 2022 were ¥2,857,915,829.17, an increase of 3.69% from ¥2,756,079,609.10 at the end of 2021[109]. - The net assets attributable to shareholders at the end of 2022 were ¥2,373,520,735.73, a decrease of 0.62% from ¥2,388,210,565.58 at the end of 2021[109]. - The operating revenue after deducting unrelated income was ¥356,182,827.24 in 2022, compared to ¥397,438,686.73 in 2021[109]. - The company reported a significant decline in both revenue and profit metrics, indicating challenges in its operational performance for the year[109]. Strategic Development and R&D - In 2023, the company aims to enhance its internal management, R&D innovation, production, and marketing capabilities to drive high-quality development[5]. - The company plans to optimize its product pipeline and advance innovative drug projects through clinical trials in 2023[6]. - The company will strengthen its production management system to ensure stable operations and enhance cost-reduction measures through technological advancements[6]. - The company intends to improve brand strength and market coverage by developing flexible product policies and innovative marketing strategies[7]. - The company acknowledges the high risks associated with new drug development, including long cycles and potential market changes affecting profitability[11]. - The company will actively seek financing channels and industry resources to support its drug development and production expansion projects[12]. - The company is committed to enhancing its product offerings and technological advancements in the upcoming fiscal year[69]. - The company aims to expand its market presence and explore potential mergers and acquisitions[69]. - The company plans to expand its market presence by increasing its investment in R&D by 20% in 2023, focusing on new biopharmaceutical products[96]. - The company is actively engaging in research and development for new products[69]. - The company has established a strategic partnership with a leading technology firm to enhance its biomanufacturing capabilities[96]. - The company is focusing on expanding its market presence and developing new products in the biopharmaceutical sector[116]. - The company is committed to expanding its market presence and enhancing its product offerings through continuous research and development efforts[152]. - The company is accelerating the research and development of second-generation nerve growth factor products to strengthen its competitive edge in the market[182]. Market and Industry Trends - The biopharmaceutical industry is expected to experience high growth due to rapid economic development and increasing health awareness in China[116]. - The biopharmaceutical industry in China is expected to exceed 4 trillion yuan in market size by 2022, driven by increasing demand due to economic development and an aging population[141]. - R&D expenditure in China's pharmaceutical manufacturing industry grew from 48.847 billion yuan in 2016 to 94.244 billion yuan in 2021, with a compound annual growth rate of 14.05%[142]. - The company operates in five major biopharmaceutical segments, including interferon, nerve growth factor, CRO/CDMO, vaccines, and pharmaceutical intermediates, ensuring stable operations across all segments[146]. - The company has a diverse vaccine portfolio including COVID-19 inactivated vaccine, EV71 inactivated vaccine, and the first hepatitis A inactivated vaccine prequalified by WHO[152]. - The company’s vaccine products are positioned to meet both domestic and international health needs, showcasing its competitive edge in the biopharmaceutical sector[152]. Human Resources and Management Changes - The company experienced a significant leadership turnover, with multiple executives resigning, including the general manager and financial director[71]. - The company has seen a significant turnover in its executive team, with multiple resignations and appointments throughout 2022[79]. - The management team includes experienced professionals with backgrounds in finance and engineering, enhancing the company's strategic capabilities[119][120]. - The company has a total of 666 employees, with 34 holding a master's degree or above, and 307 with a bachelor's degree[191]. - The company has established a performance evaluation and compensation management system for its directors and senior management, ensuring transparency and alignment with company performance[133]. Compliance and Regulatory Environment - The company has faced regulatory scrutiny in the past, with warnings issued by the China Securities Regulatory Commission for information disclosure violations[129]. - The company is committed to maintaining compliance with relevant laws and regulations to ensure sustainable growth and investor confidence[130]. - The company is focused on maintaining compliance with regulatory standards and improving internal controls, as evidenced by the self-evaluation reports presented to the board[158]. Product Development and Innovation - The company’s interferon product line includes the world's first human interferon α2b aerosol spray, which fills a gap in the antiviral field[147]. - The company’s nerve growth factor product, Enjingfu, is designed for nerve injury repair and has significant biological functions for nerve regeneration[148]. - The company has launched two new products in the oncology segment, expected to contribute an additional RMB 200 million in revenue in 2023[96]. - The company has filed 16 patents since its establishment, including 2 national invention patents and 10 utility model patents, enhancing its intellectual property portfolio[178]. - The company has received recognition for its innovative products, including being named a key new product in Tianjin[147]. - The company has received a national invention patent for its "waste gas hydrogen cyanide method" production technology, which is at the world advanced level[186].

证券代码：002581 证券简称：未名医药 山东未名生物医药股份有限公司投资者关系活动记录表 编号：20230512 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 活动类别 | □媒体采访  业绩说明会 □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称 | 网上平台"全景•路演天下"参与未名医药 2022 年度网上业绩说明会 | | | 的广大投资者 | | 时间 | 2023.5.12（15:00-17:00） | | 地点 | "全景•路演天下"（http://rs.p5w.net） | | 上市公司接待 | 董事长岳家霖先生，副总经理刘文俊先生，副总经理徐隽雄先生，独 | | 人员姓名 | 立董事肖杰先生，财务总监刘阳军先生，董事会秘书赵辉先生 | | | Q1：未名天源公司的拆迁补偿协议到底签了没有？补偿资金到 | | | 位没有？ | | | 答：尊敬的投资者，你好！公司将根据相关法律法规和《公司章 | | | 程》的相关规定履行相应审议程序和信息披露义务，请留意公司在指 | | | 定媒体发布的相关公告，谢谢。 | ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚 假记载、误导性陈述或重大遗漏。 5、其他非流动资产期末余额比年初余额增加 6579.91%，主要原因系本期预付购置资产所致。 重要内容提示： □适用 不适用 1、应收款项融资余额比年初余额增加 480.78%，主要原因系本期加大回款力度收到银行承兑汇票增加所 致。 公司是否需追溯调整或重述以前年度会计数据 （一）合并资产负债表项目变动的原因说明： 2、其他应收款期末余额比年初余额减少 64.15%，主要原因系本期收回押金所致。 山东未名生物医药股份有限公司 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 山东未名生物医药股份有限公司 2023 年第一季度报告 2 3、持有待售资产期末余额比年初余额减少 96.07%，主要原因系本期出售资产所致。 4、使用权资产期末余额比年初余额减少 98.32%，主要原因系本期偿还完融资租赁借款转固定资产所致。 证券代码：002581 证券简称：未名医药 公告编号：2023-016 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的 ...

Financial Performance - The company's operating revenue for 2022 was ¥357,080,537.01, a decrease of 11.33% compared to ¥402,713,045.66 in 2021[23]. - The net profit attributable to shareholders was -¥14,689,829.85, representing a decline of 105.42% from ¥271,001,671.69 in the previous year[23]. - The cash flow from operating activities showed a net outflow of -¥54,485,087.46, worsening from -¥46,015,293.51 in 2021, indicating an 18.41% increase in cash outflow[23]. - Basic earnings per share were -¥0.0223, down 105.43% from ¥0.4108 in 2021[23]. - Total assets at the end of 2022 amounted to ¥2,857,915,829.17, reflecting a 3.69% increase from ¥2,756,079,609.10 at the end of 2021[23]. - The net assets attributable to shareholders decreased by 0.62% to ¥2,373,520,735.73 from ¥2,388,210,565.58 in 2021[23]. - The company reported a quarterly operating revenue of ¥87,387,093.61 in Q1, ¥100,257,851.62 in Q2, ¥87,884,145.56 in Q3, and ¥81,551,446.22 in Q4 of 2022[27]. - The net profit attributable to shareholders in Q4 was -¥79,140,215.15, a significant decline compared to previous quarters[28]. - The company experienced a total of -¥6,192,154.14 in non-recurring losses for 2022, contrasting with a gain of ¥15,778,501.14 in 2021[29]. - The company reported a total distributable profit of ¥1,134,738,257.30 for the period, with no cash dividends or stock bonuses proposed[159]. Risk Factors - The company has acknowledged various risks including policy, R&D, safety, environmental, and market competition risks in its future outlook[4]. - The company emphasizes the importance of risk awareness among investors regarding future plans and performance forecasts[4]. - The company has indicated uncertainty regarding its ability to continue as a going concern, as reflected in its financial performance over the past three years[23]. - The company faces policy risks due to ongoing reforms in the pharmaceutical industry, which may lead to price reductions for some products[94]. - R&D risks are present due to the long and high-risk nature of new drug development, which may affect future profitability[96]. - The company is exposed to safety and environmental risks associated with production processes, necessitating enhanced safety management and compliance[97]. - Increased market competition is anticipated as more companies enter the pharmaceutical sector, prompting the company to enhance its competitive strategies[98]. Corporate Governance - The company strictly adheres to the provisions of the Company Law and Articles of Association regarding board member adjustments, ensuring compliance with relevant requirements[106]. - The company has established a fair and transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, gradually forming a unique compensation performance assessment system[110]. - The company maintains complete independence from its controlling shareholder in business, personnel, assets, organization, and finance, ensuring autonomous operational capabilities[115]. - The company has implemented a comprehensive information disclosure management system, ensuring accurate, timely, and complete information dissemination to all shareholders[109]. - The company held its annual general meeting with a participation rate of 52.42% and a temporary shareholders' meeting with a participation rate of 34.86%[117]. - The company has developed or revised 28 internal governance regulations during the reporting period, enhancing its governance structure[112]. - The company has a dedicated investor relations management team to handle inquiries and maintain communication with shareholders[109]. - The company has established independent recruitment, training, and performance evaluation systems for its employees, ensuring no interference from the controlling shareholder[116]. - The company has a clear boundary of property rights, owning all necessary assets for its production and operations independently[116]. - The company has committed to a cooperative and win-win approach with stakeholders, balancing the interests of society, shareholders, the company, and employees[111]. Research and Development - R&D expenditure in China's pharmaceutical manufacturing industry increased from RMB 48.847 billion in 2016 to RMB 94.244 billion in 2021, with a compound annual growth rate of 14.05%[34]. - The company operates in five major biopharmaceutical segments, including interferon, nerve growth factor, CRO/CDMO, vaccines, and pharmaceutical intermediates, ensuring stable operations across all segments[37]. - The company completed the clinical phase I trial of recombinant human nerve growth factor eye drops, which showed good systemic safety and tolerance[52]. - The company is focusing on the development of the second-generation product of nerve growth factor, enhancing its competitive edge in the market[48]. - The company has applied for 16 patents, including 2 national invention patents and 10 utility model patents, with 8 utility model patents and 4 software copyrights already protected[46]. - The R&D expenditure for 2022 was 150 million RMB, accounting for 12.5% of total revenue, with plans to increase this to 15% in 2023[138]. Market and Product Development - The biopharmaceutical industry in China is expected to grow significantly, with the market size projected to exceed RMB 4 trillion by 2022, up from RMB 3.57 trillion in 2020, indicating a strong long-term demand for pharmaceuticals[33]. - The company’s vaccine segment includes products such as the inactivated COVID-19 vaccine and the first hepatitis A vaccine prequalified by WHO, showcasing its strong position in vaccine development[42]. - The company’s nerve growth factor product, Enjingfu, is the world's first clinically approved nerve growth factor drug, highlighting its innovation in the field[39]. - The company is currently in the second phase of clinical research for a new eye drop product, which is expected to enhance future revenue and profit growth[68]. - The company is actively seeking opportunities for market expansion and potential mergers or acquisitions to enhance its competitive position[134]. - The company plans to invest 300 million RMB in new technology development over the next two years to improve production efficiency[137]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[137]. Environmental and Social Responsibility - The company strictly adheres to various environmental protection laws and standards, including the "Comprehensive Wastewater Discharge Standards" and "Industrial Enterprise Boundary Noise Emission Standards" during its operations[174]. - The company has established a wastewater treatment workshop that utilizes a multi-step treatment process, ensuring that wastewater meets discharge standards before being released to the municipal sewage treatment plant[178]. - The company has a comprehensive emergency response plan for environmental incidents, which was completed and filed with the relevant authorities in December 2020[180]. - The company actively participated in social responsibility initiatives, donating CNY 76,000 in cash and 38,464 units of medication to support patients with neurological disorders[187]. - The company has paid CNY 4,671.35 in environmental protection tax during the reporting period[182]. - The company did not experience any administrative penalties related to environmental issues during the reporting period[182]. Strategic Initiatives - The company plans to improve its production management system to ensure stable operations and enhance cost-reduction measures through technological advancements[92]. - The company intends to strengthen its product branding and increase market coverage by developing flexible product policies and innovative marketing strategies[93]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential deals[120]. - The company has approved a plan to provide guarantees for its wholly-owned subsidiaries, which may support their operational needs[146]. - The company is actively revising its internal control and audit systems to ensure compliance and improve governance standards[148].

证券代码：002581 证券简称：未名医药 公告编号：2023-025 山东未名生物医药股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）定于 2023 年 5 月 12 日（星期五）15:00-17:00 在全景网举办 2022 年度网上业绩说明会，本次年度 业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动 平台"（https://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：董事长岳家霖先生，副总经理刘文俊先 生，副总经理徐隽雄先生，独立董事肖杰先生，财务总监刘阳军先生，董事会秘 书赵辉先生。具体以当天实际参会人员为准。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 10 日（星期三）下午 17 点前将问题发送至公司电子邮箱： boardoffice2022@163.com，公司将对收到 ...

山东未名生物医药股份有限公司 2022 年第三季度报告 证券代码：002581 证券简称：未名医药 公告编号：2022-082 山东未名生物医药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 山东未名生物医药股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|--- ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥187,644,945.23, a decrease of 16.35% compared to ¥224,324,491.92 in the same period last year[26]. - The net profit attributable to shareholders for the first half of 2022 was ¥23,956,571.47, down 82.63% from ¥137,921,199.99 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,654,411.89, a decline of 85.86% compared to ¥131,953,010.59 in the same period last year[26]. - Basic earnings per share for the first half of 2022 were ¥0.0363, down 82.64% from ¥0.2091 in the same period last year[26]. - Total revenue decreased by 16.35% to ¥187,644,945.23, with the biopharmaceutical manufacturing sector contributing ¥174,370,608.93, down 22.25% year-on-year[72]. - The company's sales expenses decreased by 25.98% to ¥144,436,806.53 from ¥195,128,566.53 year-on-year[69]. - The company reported an increase in income tax expenses by 35.86%, amounting to ¥4,550,122.80 compared to ¥3,349,194.18 in the previous year[69]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a 20% year-over-year growth[146]. Assets and Investments - Total assets at the end of the reporting period were ¥2,788,848,750.76, an increase of 1.19% from ¥2,756,079,609.10 at the end of the previous year[26]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,412,167,137.05, up 1.00% from ¥2,388,210,565.58 at the end of the previous year[26]. - Long-term equity investments increased by 35.11% to ¥1,332,872,346.67, indicating a significant investment strategy[80]. - The company raised 252.27 million CNY in excess funds, with interest accrued amounting to 62.69 million CNY, totaling 314.96 million CNY as of June 30, 2022[89]. Research and Development - The company has established a comprehensive biological drug research and development system, with 14 patents obtained and 3 Class I new drug clinical approvals[65]. - The company has a robust research and development pipeline, with a focus on antiviral drugs and peptide drugs, supported by a strong independent R&D system[66]. - R&D investment decreased by 31.43% to ¥11,902,293.49, attributed to profit growth[72]. - The company is committed to enhancing its R&D capabilities and optimizing project selection to mitigate risks[104]. Market Position and Products - The company operates in the pharmaceutical manufacturing industry, focusing on six major biopharmaceutical segments, including nerve growth factor, interferon, CRO/CDMO, vaccines, pharmaceutical intermediates, and forest ginseng[37]. - The company’s subsidiary in Xiamen is developing a recombinant human NGF eye drop, which is currently in clinical phase II trials, positioning it as a leading player in the dry eye disease market[38]. - The company’s interferon products, including recombinant human interferon α2b injection and spray, have been included in emergency procurement for COVID-19 treatment in multiple regions[38]. - The company’s subsidiary, Peking Kexing, has developed several vaccines, including the first inactivated vaccine for hepatitis A in China and the first inactivated vaccine for SARS, with recent approvals for a polio vaccine and a quadrivalent influenza vaccine[41]. - The company’s pharmaceutical intermediates segment has developed a patented production process for dimethyl formamide, which is at the forefront of global technology[41]. - The company’s product portfolio includes a variety of formulations, such as the unique spray formulation of its interferon product, which stands out in the market[60]. Risks and Challenges - The company faces various risk factors, which are detailed in the report[6]. - The company faces risks related to policy changes in the pharmaceutical industry, which may affect drug pricing and market dynamics[103]. - R&D risks are highlighted due to the lengthy and uncertain process of drug development, which may impact future profitability[104]. - Environmental and safety risks are increasing due to stricter regulations and the nature of the pharmaceutical industry[104]. Corporate Governance and Compliance - The company held its first extraordinary general meeting of shareholders in 2022 with a participation rate of 34.86% on April 27, 2022[107]. - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital for the semi-annual period[108]. - The board of directors acknowledged the qualified audit opinion issued by the accounting firm for the 2021 financial report and will take measures to address the issues raised[181]. - The company will strictly adhere to legal requirements to maintain the independence of its operations and protect the interests of minority shareholders[171]. Environmental and Safety Measures - The company has implemented a wastewater treatment facility that meets discharge standards, with a total discharge of 2.42 tons/year for COD and 0.22 tons/year for ammonia nitrogen[115]. - The company has established a comprehensive environmental monitoring system, including online monitoring for wastewater and annual assessments for air emissions[119]. - The company has focused on enhancing safety and environmental protection measures, resulting in no safety production accidents in the first half of 2022[120]. Future Outlook - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 25% compared to the first half[146]. - New product launches included two innovative biopharmaceuticals, which are expected to contribute an additional 300 million RMB in revenue by the end of the year[146]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[146]. - A strategic acquisition of a local biotech firm was announced, valued at 500 million RMB, aimed at enhancing R&D capabilities[146].

山东未名生物医药股份有限公司 2022 年第一季度报告全文 证券代码：002581 证券简称：未名医药 公告编号：2022-018 山东未名生物医药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | ...

Financial Performance - The company reported a total revenue of RMB 659,735,586 for the year 2021, with no cash dividends distributed to shareholders[7]. - The company's operating revenue for 2021 was ¥402,713,045.66, representing a 45.47% increase compared to ¥276,830,417.57 in 2020[27]. - The net profit attributable to shareholders for 2021 was ¥271,001,671.69, a significant recovery from a loss of ¥195,934,412.31 in 2020, marking a 238.31% increase[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥255,223,170.55, compared to a loss of ¥181,493,839.42 in 2020, reflecting a 240.62% increase[27]. - The basic earnings per share for 2021 was ¥0.4108, a turnaround from a loss of ¥0.2970 per share in 2020, indicating a 238.32% improvement[31]. - The company's total assets at the end of 2021 were ¥2,756,079,609.10, a 12.72% increase from ¥2,444,963,143.56 at the end of 2020[31]. - The net assets attributable to shareholders increased by 12.80% to ¥2,388,210,565.58 at the end of 2021 from ¥2,117,208,893.89 at the end of 2020[31]. - The total profit reached ¥278,598,292.75, showing a significant year-on-year increase of 238.08%[65]. - The company achieved a revenue of ¥402,713,045.66, representing a year-on-year increase of 45.47%[65]. - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-over-year increase of 15%[179]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 20%[188]. - The company reported a total revenue of 45 million yuan for the fiscal year 2021, reflecting a year-over-year increase of 10%[197]. Research and Development - The company is actively involved in the development and production of biological drugs, traditional Chinese medicine, and chemical drugs[25]. - The company has a robust independent R&D system with a rich pipeline of projects, laying a solid foundation for long-term growth[60]. - The R&D investment in 2021 was ¥38,438,103.02, down 22.03% from ¥49,295,829.47 in 2020, with R&D expenses accounting for 9.54% of operating income[94]. - The company is currently conducting Phase I clinical trials for the new product Recombination NGF Eye Drops, which is expected to generate revenue and profit growth upon market launch[91]. - The company is investing 100 million RMB in R&D for new technologies in the next fiscal year[179]. - The company has established partnerships with three leading universities for collaborative research, enhancing its innovation capabilities[169]. Market Position and Strategy - The company is positioned within a rapidly developing pharmaceutical industry in China, with ongoing reforms and innovations expected to drive future growth[42]. - The company operates in the pharmaceutical manufacturing industry, with a focus on six major sectors including nerve growth factor, interferon, biopharmaceutical CRO/CDMO, vaccines, pharmaceutical intermediates, and ginseng products[48]. - The company is actively pursuing market expansion strategies, targeting new geographical regions to enhance its market presence[158]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share within the next two years[169]. - The company is exploring strategic acquisitions to bolster its product portfolio, with a budget of 500 million RMB allocated for potential deals[169]. - The company completed a strategic acquisition of a competitor for 200 million, expected to enhance its product portfolio[188]. Risks and Compliance - The company has identified key risks including policy risk, R&D risk, safety and environmental risk, and market competition risk[7]. - The company faces risks related to policy changes in the pharmaceutical industry, which could impact drug pricing and market dynamics[133]. - The company emphasizes the importance of safety and environmental compliance in its production processes to address increasing regulatory pressures[133]. - The management emphasized the importance of maintaining compliance with regulatory standards to avoid penalties, as seen in past warnings from the China Securities Regulatory Commission[198]. Governance and Management - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, organization, and finance, ensuring no reliance on the shareholder for operations[148]. - The company has established an independent financial department, adhering to effective accounting and financial management systems, with no interference from the controlling shareholder in fund usage[150]. - The board of directors and supervisory board operate independently, with all members fulfilling their duties in accordance with relevant laws and regulations[144]. - The company has a transparent performance evaluation and incentive mechanism for its directors, supervisors, and senior management, ensuring fair compensation practices[145]. - The company has implemented a robust internal control system and complies with all relevant governance regulations, ensuring effective management and oversight[143]. Product Development and Innovation - The company’s core product, the injectable mouse nerve growth factor, is the first national class I new drug in Fujian Province and the first nerve growth factor drug approved for clinical use globally[48]. - The company is actively involved in the development of new products, including a recombinant human NGF eye drop that is entering clinical phase II trials[49]. - The company’s innovative drug development is focused on expanding the applications of nerve growth factor and enhancing its core product model[48]. - The company has successfully developed a new process for producing methyl formate and methyl acetate, which is part of its commitment to circular economy and resource utilization[55]. Financial Management and Investments - The total amount of raised funds was ¥47,127.29 million, with ¥7,021.45 million utilized during the reporting period[110]. - The company has committed to invest a total of 21,900 million CNY in projects, with 15,810.47 million CNY already utilized, representing a completion rate of approximately 72.1%[115]. - The company has additional investments in projects amounting to 31,305.48 million CNY, with 28,329.11 million CNY already utilized, indicating a completion rate of about 90.5%[115]. - The company reported a total interest income of 6,247.74 million CNY from the raised funds, bringing the total funds available to 31,475.03 million CNY by the end of 2021[118]. - The company has fully utilized all raised funds by the end of 2021, with remaining interest amounting to 3,145.92 million CNY[118].

山东未名生物医药股份有限公司 2021 年第三季度报告 1 证券代码：002581 证券简称：未名医药 公告编号：2021-058 山东未名生物医药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3、第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|--------------------------|- ...